MP43-10 THE ROLE OF SURVEILLANCE BIOPSY WITH NO CANCER AS A PROGNOSTIC MARKER FOR RECLASSIFICATION: RESULTS FROM THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS) (2017)

You have accessJournal of UrologyProstate Cancer: Localized: Active Surveillance II1 Apr 2017MP43-10 THE ROLE OF SURVEILLANCE BIOPSY WITH NO CANCER AS A PROGNOSTIC MARKER FOR RECLASSIFICATION: RESULTS FROM THE CANARY PROSTATE ACTIVE SURVEILLANCE STUDY (PASS) James Kearns, Anna Faino, Lisa Newcomb, James Brooks, Peter Carroll, Atreya Dash, William Ellis, Michael Fabrizio, Martin Gleave, Todd Morgan, Peter Nelson, Ian Thompson, Andrew Wagner, Yingye Zheng, and Daniel Lin James KearnsJames Kearns More articles by this author , Anna FainoAnna Faino More articles by this author , Lisa NewcombLisa Newcomb More articles by this author , James BrooksJames Brooks More articles by this author , Peter CarrollPeter Carroll More articles by this author , Atreya DashAtreya Dash More articles by this author , William EllisWilliam Ellis More articles by this author , Michael FabrizioMichael Fabrizio More articles by this author , Martin GleaveMartin Gleave More articles by this author , Todd MorganTodd Morgan More articles by this author , Peter NelsonPeter Nelson More articles by this author , Ian ThompsonIan Thompson More articles by this author , Andrew WagnerAndrew Wagner More articles by this author , Yingye ZhengYingye Zheng More articles by this author , and Daniel LinDaniel Lin More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1320AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Many patients who are on active surveillance (AS) for prostate cancer (PCa) will have surveillance prostate needle biopsies (PNB) without any cancer evident. The prognostic meaning of these biopsies without cancer is unknown. We sought to define the association between negative surveillance PNB and risk of reclassification on AS. METHODS All men were enrolled in the Canary Prostate Active Surveillance Study (PASS). Men were included if they had Gleason ≤ 3+4 PCa and = 34% core involvement ratio at diagnosis and an on-study first surveillance PNB within 2 year of diagnosis. Reclassification was defined as an increase in primary or secondary Gleason grade and/or an increase in the ratio of biopsy cores with cancer to ≥ 34%. PNB outcomes were defined as: a) no evidence of cancer on biopsy, b) evidence of cancer on biopsy without reclassification, or c) reclassification. RESULTS 657 men met inclusion criteria. On first surveillance PNB, 214 (33%) had no cancer, 282 (43%) had cancer but no reclassification, and 161 (25%) reclassified. Of the 496 men who did not reclassify, 313 had a 2nd PNB. On 2nd PNB, 120 (38%) had no cancer, 139 (44%) had cancer but no reclassification, and 54 (17%) reclassified. In a multivariate analysis, significant predictors of future reclassification after 1st PNB were no cancer on PNB (HR = 0.50, p = 0.008), serum PSA, prostate size, and BMI (Table). Diagnostic Gleason score, maximum percentage of involved cores, race, T stage, and study site were considered and found to be non-significant. A finding of no cancer on the 2nd PNB was also associated with significantly decreased future reclassification on multivariate analysis (HR = 0.15, p = 0.003), regardless of first PNB result. CONCLUSIONS Men who have a surveillance PNB with no evidence of cancer are significantly less likely to reclassify on AS in the PASS cohort. These finding have implications for tailoring AS protocols. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e557 Advertisement Copyright & Permissions© 2017MetricsAuthor Information James Kearns More articles by this author Anna Faino More articles by this author Lisa Newcomb More articles by this author James Brooks More articles by this author Peter Carroll More articles by this author Atreya Dash More articles by this author William Ellis More articles by this author Michael Fabrizio More articles by this author Martin Gleave More articles by this author Todd Morgan More articles by this author Peter Nelson More articles by this author Ian Thompson More articles by this author Andrew Wagner More articles by this author Yingye Zheng More articles by this author Daniel Lin More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...